Monitoring total-body inflammation and damage in joints and entheses: the first follow-up study of whole-body magnetic resonance imaging in rheumatoid arthritis
Monitoring total-body inflammation and damage in joints and entheses: the first follow-up study of whole-body magnetic resonance imaging in rheumatoid arthritis
复制标题
DOI：
10.1080/03009742.2016.1231338
复制
发表时间：
2017-01-01
影响因子：
2.1
通讯作者：
Pedersen, S. J.
中科院分区：
文献类型：
--
作者：
Axelsen, M. B.;Eshed, I.;Pedersen, S. J.
目的：探讨全身磁共振成像（WBMRI）炎症和结构性病变的变化，在大多数关节和附着点类风湿关节炎（RA）患者阿达木单抗治疗。方法：WBMRI获得在第0，6，16，和52周，在52周的随访研究37例RA患者开始治疗阿达木单抗。研究了76个外周关节、23个椎间盘单位、骶髂关节和33个附着点的WBMRI的可读性和可靠性。结果：外周关节和中轴关节清晰度为82- 100%，肘关节和足小关节清晰度较低。对于附着点，72-100%可读，除了前胸壁、肘、膝和足底筋膜处的附着点。骨髓水肿（BMO）、骨侵蚀（80-100%）和附着点炎（77-100%）的阅片员内一致性较高，滑膜炎和软组织炎症（50-100%）的阅片员内一致性略低。治疗期间，所有滑膜炎、BMO和软组织炎症计数均在数值上降低。在前16周，欧洲抗风湿联盟（EULAR）反应良好的患者的26个关节滑膜炎WBMRI计数显著降低（中位数从6降至4，p
Objective: To investigate changes in whole-body magnetic resonance imaging (WBMRI) inflammatory and structural lesions in most joints and entheses in patients with rheumatoid arthritis (RA) treated with adalimumab.Methods: WBMRI was obtained at weeks 0, 6, 16, and 52 in a 52 week follow-up study of 37 RA patients starting treatment with adalimumab. Readability and reliability of WBMRI were investigated for 76 peripheral joints, 23 discovertebral units, the sacroiliac joints, and 33 entheses. Changes in WBMRI joint and entheses counts were investigated.Results: The readability of peripheral and axial joints was 82-100%, being less for elbows and small joints of the feet. For entheses, 72-100% were readable, except for entheses at the anterior chest wall, elbow, knee, and plantar fascia. The intrareader agreement was high for bone marrow oedema (BMO), bone erosion (80-100%), and enthesitis (77-100%), and slightly lower for synovitis and soft tissue inflammation (50-100%). All synovitis, BMO, and soft tissue inflammation counts decreased numerically during treatment. The 26-joint synovitis WBMRI count decreased significantly during the first 16 weeks for patients with a good European League Against Rheumatism (EULAR) response (from median 6 to 4, p